CClinicalTrials.gg
CompletedNCT01728896PICTORUpdated Sep 26, 2019

Patient-Initiated and ConTrolled Oral Refeeding (PICTOR)

An interventional study of Patient-controlled oral refeeding in Acute Pancreatitis, sponsored by University of Auckland, New Zealand. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-09-26.

Sponsored by University of Auckland, New Zealand · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The first step in treating patients with acute pancreatitis is to provide pain relief and intravenous fluids to keep them comfortable. As the pain subsides and patient starts to feel better food and fluids by mouth are restarted. This is done to rest the pancreas which is the organ that has been inflamed.

In some patients when food by mouth restarts they have pain and as a consequence they have a longer stay in hospital. It is thought that patients who have little pain and are within 24 hours of admission to hospital do well if they control their own food intake. This is in contrast to the usual treatment where the treating team advise when eating should restart.

02

Conditions studied

  • Acute Pancreatitis

Browse trials for

Keywords

  • Acute pancreatitis, nutrition
03

In context

Pancreatitis

752 studies on the registry are indexed under Pancreatitis; 181 are open to participants now.

This study's enrollment of 56 is below the median of 80 across 448 interventional studies indexed under Pancreatitis.

Browse Pancreatitis studies →

Lead sponsor

University of Auckland, New Zealand is the lead sponsor of 57 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • diagnosis of acute pancreatitis
  • age > 18 years
  • written informed consent

Exclusion criteria

Exclusion Criteria:

  • ongoing need for opiates
  • >96 hours after onset of symptoms
  • chronic pancreatitis
  • post-ERCP pancreatitis
  • intraoperative diagnosis
  • pregnancy
  • malignancy
  • received nutrition before randomisation
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Patient-controlled oral refeeding

    Patients will be allowed to drink and eat hospital food freely as tolerated.

    Other: Patient-controlled oral refeeding

  • No intervention
    Conventional management

Interventions

  • OtherPatient-controlled oral refeeding
06

What researchers measure

Primary outcomes

  1. Oral food intolerance

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days

Secondary outcomes

  1. Time from admission until tolerance of oral food

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days

  2. Total length of hospital stay

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days

  3. Need for opiates

    Need for opiates is defined when one (or more) of the following has been administered: * Codeine phosphate * Fentanyl * Morphine, Sevredol, Meslon * Oxynorm, Oxycodone * Tramadol

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days

  4. Change in pain intensity

    Time frame: Baseline and 24, 48, 72h after randomisation

  5. Progression of acute pancreatitis severity

    To be defined according to the 2012 determinant-based classification of acute pancreatitis severity

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days

  6. Hospital readmission

    Time frame: 2 weeks after hospital discharge

  7. Local and systemic complications

    To be defined according to the 2012 determinant-based classification of acute pancreatitis severity

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days

  8. Number and type of interventions during hospital stay

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days

  9. Time from admission until first flatus

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days

  10. Change in blood glucose

    Time frame: Baseline and 24, 48, 72h after randomisation

  11. Change in plasma C-reactive protein

    Time frame: Baseline and 24, 48, 72h after randomisation

07

Study locations

1 site
  • University of Auckland; Auckland City Hospital
    Auckland, New Zealand
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01728896
Lead sponsor
University of Auckland, New Zealand
Responsible party
Max Petrov (Prinicpal Investigator Dr. Max Petrov, University of Auckland, New Zealand) — Principal investigator
First posted
Nov 20, 2012
Start date
Dec 1, 2013
Primary completion
Jun 1, 2018
Completion
Jun 1, 2019
Last update
Sep 26, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion